lower
respiratori
tract
infect
lrti
lead
infecti
caus
death
sixthlead
caus
death
overal
worldwid
streptococcu
pneumonia
serotyp
remain
common
identifi
caus
communityacquir
acut
bacteri
pneumonia
antibiot
treat
lrti
bacteri
etiolog
potenti
antibioticresist
bacteria
defin
etiolog
lrti
imper
appropri
patient
treatment
creactiv
protein
procalcitonin
pointofcar
test
may
differenti
bacteri
versu
viral
etiolog
lrti
major
advanc
current
advanc
abil
make
rapid
diagnos
identif
bacteri
etiolog
lrti
continu
support
antimicrobi
stewardship
focu
review
estim
million
case
lower
respiratori
tract
infect
lrti
global
lrti
lead
infecti
caus
death
sixthlead
caus
death
overal
worldwid
alon
lrti
defin
pneumonia
bronchiti
bronchiol
caus
estim
million
death
disproportion
effect
children
younger
year
age
adult
year
old
pneumonia
due
streptococcu
pneumonia
caus
half
death
age
approxim
million
death
global
improv
mortal
rate
seen
among
children
year
old
offset
increas
lrti
diseas
burden
among
peopl
year
old
typic
bacteri
infect
associ
higher
mortal
rate
lrti
compar
infect
lrti
includ
diagnos
pneumonia
bronchiti
bronchiol
young
children
lung
alveolar
airway
infect
caus
bacteria
virus
fungi
even
parasit
preantibiot
year
bacteri
etiolog
pneumonia
commonli
due
pneumonia
incid
bacteri
etiolog
pneumonia
decreas
recent
year
especi
avail
vaccin
like
pneumococc
polysaccharid
vaccin
pneumovax
pneumococc
conjug
vaccin
prevnar
current
case
communityacquir
pneumonia
due
pneumonia
like
due
increas
vaccin
rate
pathogen
viral
etiolog
identifi
patient
mani
patient
bacteri
coinfect
viral
respiratori
pathogen
result
decreas
mucociliari
clearanc
bacteria
exampl
patholog
includ
influenza
decreas
clearanc
pneumonia
respiratori
syncyti
viru
rsv
induc
adher
cell
complic
diagnos
patient
respiratori
pathogen
frequent
detect
healthi
patient
colon
result
question
caus
role
lrti
communityacquir
pneumonia
cap
major
respiratori
diseas
high
preval
gener
popul
center
diseas
control
prevent
unit
state
evalu
etiolog
pneumonia
commun
epic
studi
financi
burden
pneumonia
unit
state
estim
approxim
billion
pathogen
identifi
adult
patient
radiolog
evid
cap
avail
specimen
diagnosi
patient
pathogen
identifi
etiolog
includ
viral
bacteri
viral
bacteri
fungal
mycobacteri
pathogen
common
rhinoviru
influenza
pneumonia
figur
pneumonia
capsular
serotyp
remain
commonli
identifi
caus
communityacquir
acut
bacteri
pneumonia
european
union
eu
case
cap
expect
annual
hospit
rate
rang
bacteri
etiolog
pneumonia
includ
streptococcu
pyogen
staphylococcu
aureu
haemophilu
influenza
usual
nontyp
klebsiella
pneumonia
although
uncommon
often
associ
comorbid
chronic
obstruct
lung
diseas
alcohol
prospect
studi
conduct
finland
etiolog
cap
children
detect
children
viral
bacteri
coinfect
pneumonia
commonli
identifi
caus
pathogen
incid
hospitalassoci
pneumonia
hap
approxim
hospit
patient
unit
state
second
common
nosocomi
infect
account
hospitalassoci
infect
deadliest
casefat
rate
approxim
nosocomi
pneumonia
infect
pathogen
report
among
pathogen
report
common
caus
nosocomi
pneumonia
aureu
figur
even
hap
gener
consid
less
sever
ventilatorassoci
pneumonia
vap
seriou
complic
occur
approxim
patient
includ
respiratori
failur
pleural
effus
septic
shock
renal
failur
empyema
base
data
report
nation
healthcar
safeti
network
center
diseas
control
prevent
aureu
account
vap
make
common
caus
vap
pathogen
lead
hapvap
includ
pseudomona
aeruginosa
enter
gramneg
bacilli
acinetobact
baumannii
identifi
caus
pathogen
acut
bronchiti
also
quit
difficult
case
caus
pathogen
acut
bronchiti
due
bacteria
includ
bordetella
pertussi
chlamydia
pneumonia
mycoplasma
pneumonia
wherea
approxim
case
due
viral
infect
adenoviru
coronaviru
parainfluenza
influenza
rhinoviru
bronchiol
occur
larg
part
infant
due
viral
etiolog
common
rsv
children
rsv
infect
year
old
antibiot
treat
lrti
bacteri
etiolog
potenti
antibioticresist
bacteria
well
sequela
use
unnecessari
antibiot
includ
clostridioid
difficil
infect
defin
etiolog
lrti
imper
appropri
patient
treatment
current
diagnost
tool
adequ
timeeffici
manner
point
care
clinic
assess
typic
deciph
bacteri
viral
etiolog
lrti
therefor
diagnost
tool
essenti
empir
treatment
current
tool
includ
use
creactiv
protein
procalcitonin
andor
combin
briefli
creactiv
protein
crp
acut
phase
reactant
synthes
liver
respons
cytokin
releas
macrophag
adipocyt
respons
inflammatori
condit
bacteri
infect
consortia
develop
interpret
cutoff
crp
level
assist
physician
antibiot
prescrib
crp
level
mgl
indic
selflimit
lrti
antibiot
need
crp
mgl
indic
sever
infect
antibiot
prescrib
crp
level
mgl
challeng
interpret
must
includ
clinic
assess
tabl
tabl
creactiv
protein
procalcitonin
level
need
antibiot
therapi
although
rapid
test
crp
use
pointofcar
set
use
crp
controversi
cochran
review
trial
conduct
throughout
europ
russia
determin
crp
level
may
reduc
use
antibiot
result
affect
patient
outcom
suggest
increas
hospit
due
crp
evalu
may
occur
although
andreeva
et
al
report
decreas
antibiot
prescrib
evalu
crp
author
discuss
multipl
studi
result
chang
therefor
util
crp
level
remain
specif
individu
treatment
set
measur
crp
substitut
clinic
assess
followup
remain
mainstay
assess
lrti
hapvap
infecti
diseas
societi
america
idsa
indic
clinic
criteria
alon
rather
use
crp
prefer
sinc
crp
result
reproduc
determin
whether
vap
bacteri
leav
clinician
reli
clinic
assess
alon
procalcitonin
pct
anoth
acut
phase
reactant
associ
bacteri
infect
pct
increas
within
h
infect
peak
h
pct
use
assist
diagnosi
sepsi
sinc
use
lrti
postop
infect
like
crp
use
target
ensur
appropri
antibiot
use
tabl
typic
pct
produc
parafollicular
cell
thyroid
neuroendocrin
cell
lung
intestin
small
quantiti
precursor
calcitonin
regul
calcium
phosphat
blood
bacteri
endokin
cytotoxin
stimul
product
earli
diseas
process
evid
shown
pct
use
method
guid
initi
durat
antibiot
treatment
lrti
metaanalysi
random
studi
major
patient
acut
lrti
show
pct
test
lower
mortal
decreas
antibiot
consumpt
day
mean
reduct
exposur
antibioticrel
advers
event
decreas
briel
et
al
evalu
patient
physician
thought
need
antibiot
respiratori
tract
infect
patient
random
pctguid
approach
antibiot
therapi
standard
approach
antibiot
prescript
rate
lower
procalcitoninguid
antibiot
use
without
impact
patient
outcom
howev
huang
et
al
conduct
studi
hospit
unit
state
among
patient
observ
signific
differ
pct
group
usualcar
group
antibiot
day
mean
day
respect
proport
patient
advers
outcom
respect
vida
brahm
test
develop
approv
fda
differenti
bacteri
viral
infect
ultim
whether
antibiot
need
pneumonia
tabl
ongo
studi
target
reduct
antibiot
use
procalcitonin
traplrti
evalu
outpati
adult
suspect
lrti
low
procalcitonin
level
low
blood
level
pct
ngml
use
vida
brahm
test
produc
result
within
min
use
inclus
criterion
patient
random
either
azithromycin
day
placebo
day
patient
evalu
improv
symptom
addit
followup
day
random
studi
evalu
recoveri
patient
given
azithromycin
versu
placebo
whether
low
pct
level
use
avoid
antibiot
therapi
studi
complet
add
evid
util
pointofcar
pct
test
patient
symptom
lrti
outpati
set
use
host
biomark
conjunct
also
studi
found
high
sensit
specif
bacteri
lrti
pointofcar
test
crp
myxoviru
resist
protein
mxa
use
patient
pharyng
lrti
determin
etiolog
infect
combin
character
bacteri
infect
viral
infect
along
neg
bacteri
viral
infect
howev
studi
small
confirm
point
care
test
need
anoth
hostprotein
signatur
assay
combin
result
tumor
necrosisfactor
relat
apoptosisinduc
ligand
trail
crp
produc
score
use
softwar
score
indic
nonbacteri
etiolog
wherea
score
predict
bacteri
infect
includ
mix
viralbacteri
coinfect
assay
sensit
specif
use
assay
superior
use
biomark
individu
develop
continu
pointofcar
platform
provid
result
within
min
major
advanc
diagnosi
bacteri
lrti
occur
past
ten
year
field
still
evolv
etiolog
determin
pneumonia
lrti
typic
challeng
base
clinic
assess
alon
addit
collect
optim
specimen
detect
pathogen
etiolog
lrti
must
consid
given
specif
test
modal
well
logist
obtain
specimen
specimen
collect
use
invas
blood
thoracentesi
transthorac
needl
aspir
bronchoscop
bronchoalveolar
lavag
protect
specimen
brush
noninvas
techniqu
induc
expector
sputum
nasopharyng
swab
oropharyngealthroat
swab
urin
antigen
test
howev
colon
respiratori
tract
variou
pathogen
must
taken
account
determin
appropri
treatment
regimen
base
sputum
nasooropharyng
swab
studi
patient
cap
cultur
rtpcr
use
compar
plasma
respiratori
nasopharyng
swab
sputum
tracheal
aspir
sampl
studi
rtpcr
plasma
respiratori
sampl
identifi
pneumonia
often
cultur
howev
good
qualiti
sputum
sampl
often
challeng
obtain
especi
outpati
set
children
gold
standard
identif
bacteri
viral
fungal
pathogen
remain
cultur
bacteri
pathogen
test
antimicrobi
suscept
also
conduct
ensur
adequ
therapi
administ
howev
cultur
suscept
often
take
multipl
day
obtain
result
day
includ
expos
patient
possibl
ineffect
therapi
signific
safeti
repercuss
initi
inappropri
treatment
identifi
risk
factor
increas
mortal
rate
patient
habpvabp
therefor
diagnost
method
evalu
assist
provid
time
diagnos
tabl
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
anoth
modal
use
diagnos
bacteri
lrti
approxim
one
isol
singl
coloni
cultur
plate
analyz
malditof
ms
autom
workflow
result
avail
within
minut
identifi
microorgan
base
match
librari
microorgan
two
malditof
ms
system
approv
food
drug
administr
fda
includ
vitek
ms
inc
identifi
speci
includ
mycobacteria
well
maldi
biotyp
ca
system
bruker
dalton
inc
identifi
speci
speci
group
repres
bacteria
yeast
speci
speci
identifi
differ
system
studi
compar
two
system
system
correctli
identifi
strain
test
gramposit
bacteria
gramneg
bacteria
mycobacteria
aerob
actinomycet
yeast
mold
includ
microorgan
associ
lrti
maldi
biotyp
ca
smaller
desktop
technolog
compar
larger
vitek
ms
drawback
malditof
ms
technolog
potenti
overdiagnosi
depend
coloni
select
test
lack
abil
identifi
new
pathogen
primari
antibiot
suscept
test
conduct
use
either
autom
kirbybau
test
etest
method
supplement
test
antimicrobi
suscept
test
ast
reagent
strip
determin
minimum
inhibitori
concentr
recent
selux
develop
next
gener
phenotyp
ngp
platform
highthroughput
fullyautom
ast
test
system
enabl
sameshift
suscept
test
antibiot
parallel
assay
differenti
antibioticinduc
bacteri
growth
mode
surfacebind
fluoresc
amplifi
serolog
test
particularli
sensit
specif
come
diagnos
atyp
bacteria
pneumonia
howev
nucleic
acid
amplif
test
naat
anoth
test
modal
includ
standard
polymeras
chain
reaction
pcr
provid
rapid
highli
sensit
specif
result
recent
addit
naat
diagnost
armamentarium
includ
pcr
multiplex
realtim
read
fdaapprov
diagnosi
lrti
panel
test
sampl
obtain
result
within
h
reduc
time
need
confirm
causal
pathogen
lrti
unyvero
lrt
cartridg
approv
fda
detect
pathogen
associ
pneumonia
hospit
patient
well
genet
antibiot
resist
marker
endotrach
aspir
sampl
lrt
cartridg
panel
sensit
specif
across
lower
respiratori
tract
panel
pathogen
firstinclass
molecular
test
lrti
first
autom
molecular
diagnost
test
approv
fda
legionella
pneumonia
futur
fda
approv
sought
expand
sampl
includ
bronchoalveolar
lavag
aspir
expand
assay
includ
pneumocysti
jirovecii
addit
develop
smaller
unit
unyvero
rq
process
faster
result
within
min
use
realtim
pcr
anoth
realtim
pcr
test
recent
approv
fda
includ
biofir
filmarray
system
rtpcrnest
multiplex
pcr
pneumonia
panel
plu
bio
assay
detect
bacteria
gram
neg
four
gram
posit
three
atyp
seven
antibiot
resist
marker
nine
virus
caus
pneumonia
lrti
seven
genet
marker
antibiot
resist
within
h
use
sputum
includ
endotrach
aspir
bronchoalveolar
lavag
includ
minib
sampl
type
sensit
assay
specif
pneumonia
panel
receiv
fda
clearanc
cemark
novemb
although
pcr
test
compromis
due
contamin
quantit
result
help
determin
whether
result
due
contamin
clinic
relev
infecti
etiolog
approv
panel
provid
semiquantit
result
biofir
filmarray
system
pneumonia
panel
plu
report
level
organ
concentr
genom
copiesml
valu
copiesml
bacteri
pathogen
addit
naat
provid
viral
bacteri
rapid
assess
particularli
help
diagnos
lrti
name
pneumonia
infiltr
chest
xray
bacteri
viral
coinfect
certainli
need
ruledout
patient
pneumonia
therefor
abil
determin
viral
bacteri
etiolog
advantag
howev
naat
limit
includ
constant
need
keep
intern
refer
updat
bacteria
virus
metagenom
sequencingbas
shotgun
diagnost
compar
sampl
known
organ
resist
pattern
intern
databas
rather
shotgun
metagenom
method
involv
extract
total
dna
andor
rna
usual
follow
convers
dna
primari
specimen
fragment
librari
prepar
depth
sequenc
charalamp
et
al
report
optim
nanopor
sequencingbas
clinic
metagenom
test
oxford
nanopor
technolog
remov
approxim
host
dna
clinic
respiratori
sampl
challeng
specimen
given
low
pathogen
load
compar
backdrop
host
nucleic
acid
sputum
enabl
pathogen
genom
assembl
equival
whole
genom
sequenc
isol
within
h
would
allow
identif
new
pathogen
emerg
unusu
resist
pattern
well
outbreak
assess
method
test
current
remain
develop
urin
antigen
test
also
avail
select
pathogen
rapid
result
less
h
enzym
immunoassay
later
flow
assay
use
detect
serogroup
legionella
pneumophilia
strain
common
caus
infect
enzym
immunoassay
avail
pneumonia
detect
know
patient
lrti
treat
treat
challeng
determin
physician
often
err
side
caution
prescrib
antibiot
given
high
mortal
rate
bacteri
lrti
often
without
diagnost
result
patient
empir
treat
antibiot
preemptiv
avoid
sever
complic
bacteri
lrti
improv
diagnosi
etiolog
infect
would
enabl
target
therapi
lead
overal
judici
use
antibiot
would
like
decreas
rate
antimicrobi
drug
resist
well
safeti
impact
inappropri
treatment
modal
patient
due
improp
treatment
lrti
infect
patient
may
treat
adequ
respons
bacterium
pneumonia
methicillinresist
aureu
gramneg
bacilli
resist
avail
antibiot
leav
physician
without
weapon
combat
ill
prudent
use
avail
antibiot
patient
anim
give
need
correct
diagnosi
etiolog
understand
correct
dosag
dose
interv
durat
imper
antimicrobi
stewardship
base
premis
million
cours
outpati
antibiot
therapi
prescrib
half
antibiot
unnecessari
inappropri
use
acut
respiratori
infect
includ
acut
bronchiti
research
rapid
patientfriendli
inexpens
access
diagnost
modal
appropri
character
lrti
bacteri
versu
viral
versu
necessari
har
antibiot
use
addit
determin
caus
bacteri
pathogen
antibiot
stewardship
program
lower
risk
propag
resist
unwant
advers
event
includ
develop
c
difficil
advanc
note
certainli
move
right
direct
understand
etiolog
pneumonia
rapid
manner
develop
still
continu
even
faster
comprehens
test
